The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Farmout Agreement signed in Foum Assaka Block

18 Dec 2013 07:00

RNS Number : 8101V
Fastnet Oil & Gas PLC
18 December 2013
 



18th December 2013

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Fastnet Executes Farmout Agreement for Foum Assaka Contract Area, offshore Morocco with South Korean company SK Innovation

 

Highlights

· Farmout agreement entered into with Korean-listed SK Innovation (096770.KS), an affiliate of SK Group the third largest conglomerate in South Korea, for half of Fastnet's interest, in the Foum Assaka Contract Area, offshore Morocco;

· Up to two well carry comprised of a carry in the first exploration well on the Eagle Prospect and first appraisal well (capped at US$100 million per well) or at SK Innovation's discretion a carry in a second exploration well (capped at US$100 million);

· Reimbursement of past costs of US$3.2 million and a further payment of 25 per cent of Fastnet's back costs relating to the period from 1 October to 1 January 2014.

Fastnet (AIM: FAST, ESM: FOI) the listed E&P company focused on near term exploration acreage in Morocco and the Celtic Sea, is pleased to announce that its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited ("Pathfinder") has signed a farmout agreement ("Farmout Agreement") with South Korean company SK Innovation for a 12.5 per cent paying interest share over four exploration licenses comprising the Foum Assaka offshore Contract Area in the Agadir Basin in Morocco ("Foum Assaka Block").

Following the completion of the Farmout Agreement and the receipt of all regulatory approvals, the equity split for the Foum Assaka Block will be:

Party

Participating Interest

Paying Interest

Kosmos Energy Deepwater Morocco ("Kosmos") (Operator)

29.925%

39.900%

BP Plc ("BP")2

26.325%

35.100%

Pathfinder

9.375%

12.500%

SK Innovation

9.375%

12.500%

ONHYM1

25.000%

0.00%

Notes:

1. ONHYM will have a carried interest through the exploration period.

2. BP farmin currently in process and subject to Moroccan government approvals

 

Commercial terms

Under the terms of the Farmout Agreement, SK Innovation will acquire a 12.5 per cent interest in the Foum Assaka Block and shall pay 100 per cent of Pathfinder's 12.5 per cent share of the cost of the first exploration well subject to a maximum gross well cost of US$100 million.

In the event that the second well, following the initial exploration well, is not an appraisal well but a further exploration well then, at SK Innovation's election to participate, SK Innovation shall pay 100 per cent of Pathfinder's 12.5 per cent share of the cost of the second well subject to a maximum gross well cost of US$100 million.

If the gross costs in either of the two wells are less than US$100 million then, provided Fastnet and SK Innovation agree to re-drill the same prospect, SK Innovation shall carry Fastnet until such time as the cumulative gross cost for both wells reach US$100 million.

Under the Farmout Agreement, SK Innovation shall pay to Fastnet the sum of US$3,220,900, which represents a 25 per cent share of costs incurred by Pathfinder up until 1 October 2013. In addition, SK Innovation shall pay 25 per cent of actual costs incurred by Pathfinder from 1 October 2013 to 1 January 2014 and any pre-drill costs directly attributable to the FA-1 well being the first well drilled on the Eagle prospect. SK Innovation shall also pay 12.5 per cent of Pathfinder's costs in relation to its participating interest during the period from 1st January 2014 until the issue of a Joint Ministerial Order approving the assignment of the 12.5 per cent participating interest from Pathfinder to SK Innovation ("Completion").

Completion of the farm-out is subject to the customary closing conditions including:

· SK Innovation obtaining any required approvals from the government of the Republic of Korea;

· Moroccan Government approval;

· Waiver of existing pre-emption rights by the Foum Assaka joint venture partners; and

· Confirmation from the parties to the Joint Operating Agreement ("JOA") approving the terms of the novation agreement in respect of the JOA and assignment of the interest in the Foum Assaka Block to SK Innovation.

Expected drilling timetable

Currently the operator, Kosmos, anticipates a late Q1 2014 spud date for a well on the Eagle Prospect to test all prospective reservoirs.

Background information on SK Group

SK Innovation (formerly known as SK Energy) is the energy and chemicals affiliate of SK Group. The SK Group is the third largest conglomerate in South Korea with over 70,000 employees who work from 113 offices worldwide. The group's businesses include energy, chemicals, information, telecommunications, semiconductors, finance, and distribution.

 

Carol Law, Executive Director of Fastnet said:

"The farmout of half of our Interest in the Foum Assaka Block provides Fastnet with a very low cost opportunity to participate in the drilling of a high profile, potentially high reward well in what we view as one of the industry's hottest new exploration areas. This transaction validates Fastnet's strategic decision to conduct a separate competitive farmout process for its equity interest in this highly regarded exploration block in the Agadir Basin, as exemplified by BP's farm-in to the Kosmos equity. Fastnet has secured excellent commercial terms and has ensured that the carried equity interest has running room in the event of a follow up appraisal or exploration well being drilled."

 

Paul Griffiths, Managing Director of Fastnet said:

"The Farmout Agreement significantly strengthens Fastnet's balance sheet and ensures that our exciting offshore and onshore drilling programme in Morocco in H1 2014 can be optimally executed in a manner consistent with the Company's stated strategy of returning value to shareholders in the event of early drilling success."

 

There will be a conference call for analysts held by management at 9.00 am this morning to discuss the transaction. The recording of the call will be uploaded to www.fastnetoilandgas.com later today.

 

For further information please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

 

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

 

Corporate Broking

Jerry Keen

 

+44 (0) 20 7408 4090

GMP Securities Europe LLP

(Joint Broker)

Rob Collins

 

+44 (0)20 7467 2800

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

 

+353 (1) 679 6363

FTI Consulting

Edward Westropp, Natalia Erikssen, James Styles

+44 (0) 207 831 3113

 

 

Notes to editors

About SK Innovation

SK Innovation (formerly known as SK Energy) is the energy and chemicals affiliate of SK Group. The SK Group is the third largest conglomerate in South Korea with over 70,000 employees who work from 113 offices worldwide. The group's businesses include energy, chemicals, information, telecommunications, semiconductors, finance, and distribution.

 

SK Innovation has been leading Korea's energy industry for the past five decades. Early on, the company expanded into overseas resource exploration. These efforts have seen tangible results in projects in Vietnam, Peru, Brazil and elsewhere, elevating the company's global stature in natural resource development.

 

SK Innovation has been actively involved in a number of overseas E&P projects in Yemen, Vietnam, Peru and Brazil, helping turn the company into a reliable E&P partner with global players through the success of its several business models. By actively exploring and acquiring shares in new and prospective operations, SK Innovation has vastly strengthened its E&P business portfolio, which now ranges from exploration and development to production.

 

After a successful disposal of assets in Brazil in 2011, SK Innovation had significantly more liquidity for expanding its E&P business. Buoyed by this success, the company started looking for more M&A opportunities and operations sites commensurate with its asset volume and technologies.

 

SK innovation is actively participating in 24 blocks and four LNG projects in 16 countries and has a high-value asset of 646 mmboe (Proven Reserves, P1), with stable production volume of 72,000 b/d in 3Q13.

 

(Sources: SK Innovation website, 2012 Annual Report and 2013 Presentation to Investors)

 

About Fastnet

Fastnet Oil & Gas plc is an independent oil and gas exploration company that focuses on identifying early stage exploration and appraisal opportunities in Offshore Morocco and Ireland. It is quoted on the AIM market of the London Stock Exchange and the Enterprise Securities Market (ESM) of the Irish Stock Exchange. Fastnet's aim is to assemble a portfolio of high impact conventional oil and gas assets that will deliver sustainable growth and value for the Company. Its immediate focus is on implementing its Offshore Morocco and Ireland strategies where it holds a material interest in the Foum Assaka Block alongside an exclusive option agreement over the Tendrara-Lakbir Licence which covers 8 exploration blocks. In the Celtic Sea, Fastnet holds licensing options (Molly Malone, Shanagarry, 49/13, Mizzen and Mizzen East Basin) and an exclusive option to farm-in to the Deep Kinsale Prospect beneath the Kinsale Head gas field. In addition, Fastnet will continue to pursue new conventional oil and gas opportunities in and Africa where the Directors and Advisory Board also have extensive knowledge, contacts and experience of creating value.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRNKODNNBDBPBD
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.